Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Low Grade Serous Ovarian Cancer × defactinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 7 Ovarian Neoplasms 4 Mesothelioma, Malignant 4 Carcinoma, Non-Small-Cell Lung 4 Neoplasms 2 Mesothelioma 2 Lung Neoplasms 2 Glioblastoma 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Phase IB 1 Neoplasms, Mesothelial 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Melanoma 1 Low-Grade Serous Ovarian Cancer 1 Low Grade Serous Ovarian Cancer 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Acute 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Endometrioid 1 Brain Neoplasms 1 Advanced Colorectal Cancer 1 Adenoma 1 Adenocarcinoma of Lung 1

Interventions

liposomal doxorubicin 1 defactinib 1 Paclitaxel 1 Letrozole 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06072781 2026-03-17

RAMP 301

Verastem, Inc.

Phase 3 Recruiting

Low Grade Serous Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡